Core Viewpoint - Hims & Hers Health is set to offer a compound formulation of Novo Nordisk's weight loss drug Wegovy at a significantly lower price, leading to a notable increase in its stock price while impacting Novo Nordisk negatively [1] Group 1: Company Developments - Hims & Hers Health shares surged over 16% in pre-market trading following the announcement of the new compound formulation [1] - The compound formulation will be priced at $49 per month, which is approximately $100 cheaper than the brand-name drug Wegovy [1] - Patients opting for a five-month subscription will pay a one-time lower fee, followed by monthly payments of $99, compared to Novo Nordisk's $199 [1] Group 2: Market Reactions - Novo Nordisk's stock fell over 6% in response to the news regarding Hims & Hers Health's new offering [1] - Eli Lilly's shares also experienced a decline of over 4%, indicating a broader market reaction to the competitive pricing in the weight loss drug sector [1]
美股异动丨Hims&Hers Health推出Wegovy复方制剂，诺和诺德、礼来盘前跳水
Ge Long Hui A P P·2026-02-05 14:08